Advertisement

Introduction

  • James Rickard
  • Nik Sheng DingEmail author
  • Peter De Cruz
Chapter

Abstract

Inflammatory bowel disease (IBD), comprised largely of ulcerative colitis (UC) and Crohn’s disease (CD), is a complex, polygenic, heterogeneous group of diseases with great variation in phenotypic expression. Due to this variation, opportunities for personalised medicine, also known as ‘precision medicine’, are afforded at practically every step of IBD management, including diagnosis, risk stratification, drug selection and optimisation and prediction and management of IBD-related complications. Central to translating the promise of personalised medicine into improved IBD management are biomarkers (Fig. 1.1). As measurable or detectable markers of biological processes, biomarkers allow the characterisation and quantification of genetic predisposition, drug metabolism and response, disease activity and adverse drug effect monitoring. Ideally, biomarkers are noninvasive, safe, cost-effective and easily used, important factors for IBD patients where endoscopy and radiological imaging are often relied upon with significant risk, expense and inconvenience. Despite their clear utility, optimally selecting biomarkers from a practically infinite number of possibilities is challenging. Rapidly evolving scientific platforms offer rich opportunities for biomarker discovery, but the associated analysis of vast data readouts can be unwieldly. This introductory section will broadly outline various approaches to biomarker discovery, with a particular view to the translation of such efforts into improved personalised medicine for IBD patients. The structure of the book will also be outlined.

References

  1. 1.
    Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994–1004.  https://doi.org/10.1038/ajg.2014.110.CrossRefPubMedGoogle Scholar
  2. 2.
    De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–17.  https://doi.org/10.1016/S0140-6736(14)61908-5.CrossRefPubMedGoogle Scholar
  3. 3.
    Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine. Gut. 2002;51(2):143–6.CrossRefGoogle Scholar
  4. 4.
    Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-alpha agents in inflammatory bowel disease. Expert Opin Drug Saf. 2017;16(3):303–17.  https://doi.org/10.1080/14740338.2017.1269169.CrossRefPubMedGoogle Scholar
  5. 5.
    Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2017;  https://doi.org/10.1007/s12328-017-0813-5.CrossRefGoogle Scholar
  6. 6.
    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–3.  https://doi.org/10.1126/science.1135245.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, et al. A functional genomics predictive network model identifies regulators of inflammatory bowel disease. Nat Genet. 2017;49(10):1437–49.  https://doi.org/10.1038/ng.3947.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Aebersold R, Hood LE, Watts JD. Equipping scientists for the new biology. Nat Biotechnol. 2000;18(4):359.  https://doi.org/10.1038/74325.CrossRefPubMedGoogle Scholar
  9. 9.
    Gannon F. Goal-oriented research. EMBO Rep. 2003;4(12):1103.  https://doi.org/10.1038/sj.embor.embor7400039.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Aragon R. Thinking outside the box: fostering innovation and non-hypothesis-driven research at NIH. Sci Transl Med. 2011;3(70):70cm5.  https://doi.org/10.1126/scitranslmed.3001742.CrossRefPubMedGoogle Scholar
  11. 11.
    Mazzocchi F. Could Big Data be the end of theory in science? A few remarks on the epistemology of data-driven science. EMBO Rep. 2015;16(10):1250–5.  https://doi.org/10.15252/embr.201541001.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schmidt B, Hildebrandt A. Next-generation sequencing: big data meets high performance computing. Drug Discov Today. 2017;22(4):712–7.  https://doi.org/10.1016/j.drudis.2017.01.014.CrossRefPubMedGoogle Scholar
  13. 13.
    Boyapati RK, Kalla R, Satsangi J, Ho GT. Biomarkers in search of precision medicine in IBD. Am J Gastroenterol. 2016;111(12):1682–90.  https://doi.org/10.1038/ajg.2016.441.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • James Rickard
    • 1
  • Nik Sheng Ding
    • 2
    • 3
    • 4
    Email author
  • Peter De Cruz
    • 5
    • 6
  1. 1.Department of GastroenterologyAustin HealthMelbourneAustralia
  2. 2.St Vincent’s HospitalMelbourneAustralia
  3. 3.The University of MelbourneMelbourneAustralia
  4. 4.Imperial CollegeLondonUK
  5. 5.Department of GastroenterologyAustin HealthMelbourneAustralia
  6. 6.Department of MedicineThe University of MelbourneMelbourneAustralia

Personalised recommendations